Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for Drug-Refractory Irritability in ASD
NCT02081027Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Riluzole with Placebo (2 arms). Primary endpoints: Clinical Global Impression-Improvement at 12 weeks and Aberrant Behavior Checklist- Irritability at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
riluzole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02081027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081027.